FDA slaps Im­prim­is­Rx with a warn­ing let­ter over spon­sored ar­ti­cles in med­ical jour­nals

Im­prim­is­Rx is in hot wa­ter with the FDA for false and mis­lead­ing claims about its com­pound­ed drug for post­op­er­a­tive eye pain called Pred-Moxi-Brom.

Spon­sored ar­ti­cles …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER